Thoracic oncologists are working through the fine print of the TREASURE trial — @jryckman3 flagged its very large treatment volumes (mean PTV 460 cc, on par with the ~460 cc median in the definitive PACIFIC-2 NSCLC trial). Alongside the trial talk, @NarjustFlorezMD opened a discussion on lifestyle medicine in lung cancer, and @Joshua_Reuss announced an interesting upcoming session at #DCLung26 on best practices in unresectable NSCLC (presented by @NitikaPaudel).
“Another important TREASURE detail: the mean PTV was 460 cc. For scale, PACIFIC-2, a definitive NSCLC trial, reported a median PTV of approximately 460 cc. These were very large thoracic treatment volumes, even if protocol-concordant, and target volume should be considered when”
— @jryckman3 · TREASURE trial PTV · View post ↗
“Let’s talk about lifestyle medicine and lung cancer.”
— @NarjustFlorezMD · Lifestyle medicine · View post ↗
“Hear from Dr. @NitikaPaudel on best practices in unresectable NSCLC.”
— @Joshua_Reuss · Unresectable NSCLC · View post ↗📌 Amplified by @KolPulseAI
Breast oncologists spotlighted a practice-relevant metastatic option and adjuvant risk data. @sbkim712's phase III OPTIMAL trial — now in print in Annals of Oncology — showed oral paclitaxel (DHP107) is non-inferior to weekly IV paclitaxel in HER2-negative metastatic breast cancer, with less neuropathy and no infusion, and is now MFDS-approved in Korea. @hoperugo amplified the result and noted her complementary US phase II OPERA trial of the same oral agent. Separately, @PTarantinoMD shared a new #JNCI analysis of over 7,000 HR+/HER2- early breast cancer patients (Flatiron), reporting 7-year recurrence rates of 14% in N1 and high-risk N0 disease and up to ~40% in N2-3 — data he frames as support for adjuvant CDK4/6 inhibition.
“Our OPTIMAL trial is now in print in the July 2026 @Annals_Oncology oral paclitaxel (DHP107) is non-inferior to weekly IV paclitaxel in HER2− metastatic breast cancer — same efficacy, less neuropathy, no infusion. Now MFDS-approved in Korea (weekly). #BCSM”
— @sbkim712 · OPTIMAL phase III / oral paclitaxel · View post ↗
“Great to see this in print! Congrats! Our US phase II OPERA trial also published this year with DHP107 showing non-inferiority to IV paclitaxel in mBC; complementary to Optimal. BCRT 2026 @OncoAlert”
— @hoperugo · OPERA — complementary US phase II · View post ↗
“What is the real-world risk of recurrence from HR+/HER2- EBC? In our latest #JNCI article, including data from >7000 pts (Flatiron) we report 7y recurrence rates of 14% for N1 and N0 high-risk pts and up to ~40% in N2-3, supporting use of adjuvant CDK4/6i.”
— @PTarantinoMD · HR+/HER2- EBC recurrence · View post ↗The GI oncology community is discussing a post-hoc analysis of the TOPAZ-1 trial, which showed a 48-month overall survival rate of 11.8% with durvalumab plus chemotherapy in advanced biliary tract cancer. Additionally, the Phase 3 PERISCOPE II trial in gastric cancer with limited peritoneal metastases showed no survival benefit for gastrectomy plus cytoreductive surgery and HIPEC versus systemic chemotherapy alone. New Pan-Asian adapted ESMO clinical practice guidelines for HCC were also a topic of conversation.
“👉48-mo OS rate 11.8% vs 4.3%”
— @ArndtVogel · TOPAZ-1 in Biliary Tract Cancer · View post ↗📌 Amplified by @KolPulseAI
“👉No survival benefit with gastrectomy + cytoreductive surgery + HIPEC”
— @DaisukeKotani · PERISCOPE II in Gastric Cancer · View post ↗
“🌏 Pan-Asian adapted @myESMO Clinical Practice Guidelines for #HCC”
— @DraMartinezLago · HCC Guidelines · View post ↗The GU oncology community is discussing the FDA's expanded approval of enfortumab vedotin plus pembrolizumab for all cystectomy-eligible patients with muscle-invasive bladder cancer. Other topics include long-term follow-up from the OMNIVORE study in RCC, which found half of patients can remain off-therapy after nivolumab induction, and a post-hoc analysis of ARASENS suggesting age alone should not preclude triplet therapy in mHSPC.
“1) 50% of patients with #RCC can stay off-therapy with durable remissions after PD-1 inh. nivolumab induction”
— @DrChoueiri · OMNIVORE study in RCC · View post ↗
“Age alone shouldn't gate triplet therapy in mHSPC. The ARASENS subgroup data make that case directly.”
— @katy_beckermann · ARASENS trial in mHSPC · View post ↗
“#FDA expanded EV + pembrolizumab to all cystectomy-eligible muscle-invasive bladder cancer patients.”
— @ozdogan_md · EV+pembrolizumab approval in MIBC · View post ↗📌 Amplified by @KolPulseAI
The FDA has accepted Bristol Myers Squibb’s New Drug Application for the oral CELMoD mezigdomide plus carfilzomib and dexamethasone (MeziKd) in relapsed/refractory multiple myeloma — now under FDA review (PDUFA target May 13, 2027; not yet approved), backed by the Phase 3 SUCCESSOR-2 trial (PFS 18.0 vs 8.3 months, HR 0.48, p<0.0001). The myeloma/hematology community is discussing the recent FDA approval of an on-body injector (OBI) for Isatuximab, offering a new delivery method for the drug. Additionally, a new Phase 2 randomized trial (EAA241) has been announced to compare Dara-Bor-Dex versus Cy-Bor-Dex in newly diagnosed multiple myeloma patients with light chain cast nephropathy (LCCN), with study activation planned for August 11, 2025.
“The FDA approved OBI for Isatuximab yesterday-A New Way to Deliver Isatuximab in #Myeloma: Safety Insights on the On-Body Injector (OBI)”
— @MyelomaTeacher · Isatuximab OBI Approval · View post ↗📌 Amplified by @KolPulseAI
“EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN)”
— @mtmdphd · EAA241 Trial Activation · View post ↗The hematology community is discussing new data published in The Lancet on CD22-targeted CAR T-cells for patients with DLBCL who have relapsed after CD19-CAR T therapy. A study of 38 patients showed a 53% complete response rate and a median duration of response of 27.8 months among responders. Other topics include harmonizing first-line trial design in Large B-cell Lymphoma and leukemia trial highlights from EHA2026, such as OPTI-AML, KOMET-007, and SENTRY.
“CD22-targeted CAR T-cells in pts w DLBCL relapsed post CD19-CAR T 38 pts ORR 68% CRR 53% mDOR 27.8 months among responders”
— @Eddie_Cliff · CD22 CAR-T in post-CD19 DLBCL · View post ↗📌 Amplified by @KolPulseAI
“The Chaos of Choice in Large B-cell Lymphoma: A Call to Harmonize First-line Trial Design”
— @S_Corcoran · Large B-cell Lymphoma trial design · View post ↗
“Leukemia Highlights from #EHA2026 w/ @EuniceWangMD ⭐️ OPTI-AML ⭐️ KOMET-007 ⭐️ SENTRY”
— @OncBrothers · Leukemia trials from EHA2026 · View post ↗📌 Amplified by @KolPulseAI